Kayne Anderson Rudnick Investment Management
NBIX icon

Kayne Anderson Rudnick Investment Management’s Neurocrine Biosciences NBIX Stock Holding History

Kayne Anderson Rudnick Investment Management’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-50
Closed -$5K – 655
2022
Q1 		$5K Buy
50
+49
+4,900% +$4.15K ﹤0.01% 567
2021
Q4 		$0 Buy
+1
New +$92 ﹤0.01% 650
2021
Q1 		– Sell
-13
Closed -$1K – 669
2020
Q4 		$1K Buy
+13
New +$1.26K ﹤0.01% 635

Other funds holding NBIX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
EVM
Eaton Vance Management Boston, Massachusetts $67.5B AUM 11.44% 1-Year Est. Return

Kayne Anderson Rudnick Investment Management's NBIX Position: Q2 2022 in Review

Kayne Anderson Rudnick Investment Management sold out of Neurocrine Biosciences (NBIX) in Q2 2022, closing a stake of 50 shares — an estimated $5K sold.

Kayne Anderson Rudnick Investment Management first reported a position in NBIX in Q4 2020 and held it in 3 quarters. The position peaked at $5K in Q1 2022. 438 funds tracked by Wall St. Rank hold NBIX as of Q2 2022.

  • Kayne Anderson Rudnick Investment Management reported no remaining Neurocrine Biosciences position as of Q2 2022 after selling out during the quarter.
  • Kayne Anderson Rudnick Investment Management sold 50 Neurocrine Biosciences shares in Q2 2022, an estimated $5K.
  • Kayne Anderson Rudnick Investment Management first reported a position in Neurocrine Biosciences in Q4 2020 and held it in 3 quarters.
  • Kayne Anderson Rudnick Investment Management's Neurocrine Biosciences position peaked at $5K in Q1 2022.
  • 438 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2022.

Based on Kayne Anderson Rudnick Investment Management's 13F filing for Q2 2022, filed 12 Aug 2022.